Company Overview
Snapshot
Founded in November 2016, SpliSense operates with 11–50 employees. The company has raised a total of $54.5M across 5 funding rounds from 6 investors. In June 2026, SpliSense secured up to $13M in funding from the Cystic Fibrosis Foundation to advance its Phase 2b study for SPL84, a treatment for cystic fibrosis.
Business overview
SpliSense is a clinical-stage biotechnology company developing RNA-based treatments for pulmonary diseases, leveraging Antisense Oligonucleotide (ASO) technology delivered via inhalation. The company focuses on innovative therapies, from discovery to IND, to target the root cause of genetic diseases by overcoming specific genetic mutations and modulating protein expression and function. SpliSense operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Medical Biotechnology, with a focus on Drugs Discovery & Development.
Strategic signal
In June 2026, SpliSense secured up to $13 million from the Cystic Fibrosis Foundation to advance its Phase 2b study of SPL84 for cystic fibrosis, following positive results from an initial efficacy trial. This significant investment and the positive trial data validate the potential of SpliSense's RNA-based therapy and signal strong progress towards bringing a new treatment option to market for cystic fibrosis patients.
Log in to access full profile ›Company Intelligence Q&A
- What is the most recent funding SpliSense received?
- In June 2026, SpliSense secured up to $13 million in funding from the Cystic Fibrosis Foundation to advance its Phase 2b study of SPL84 for cystic fibrosis.
- What regulatory designation did SpliSense receive for SPL84 in May 2024?
- In May 2024, SpliSense received FDA Fast Track Designation for SPL84 for the treatment of cystic fibrosis.
- What was the outcome of the Phase 2 study for SPL84 announced in September 2025?
- In September 2025, SpliSense reported positive results from its Phase 2 study of SPL84 in cystic fibrosis.
- Which organization granted SpliSense an early PRIME designation for SPL84 in March 2026?
- In March 2026, SpliSense was granted EMA early PRIME designation for SPL84 in cystic fibrosis.
- When did SpliSense receive Orphan Drug Designation for SPL84-23-1 from the FDA and EMA?
- In January 2022, SpliSense announced that the FDA and EMA granted Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis.